ChemoMetec A/S CHEMM

ChemoMetec AS (STU:CHY) posted record DKK511 million revenue with a 55% EBITDA margin, but management's conservative FY26/27 outlook and rising CapEx keep investors guessing.

16 September 2026ANNOUNCEMENT NO. 315 Major shareholder announcement - BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock, Inc., on 14 September 2026, increased its total holding in ChemoMetec A/S to 15.00%, and that the holding thus has reached the 15 per cent limit in Section 38 of the Capital Markets Act. Additional information Martin Helbo Behrens, CEOTel.: (+45) 81 10 06 80 Phillip Massie

ANNOUNCEMENT NO. 31310 September 2026 Annual Report 2025/26 (1 July 2025 - 30 June 2026) Positioning ChemoMetec for future growth Despite changes and uncertainty affecting ChemoMetec's markets, revenue grew by 3% to DKK 511.1 million in 2025/26 whilst EBITDA grew from DKK 258.0 million to DKK 281.3 million. The growth was driven by increased sales of new instruments and services, with sales of XcytoMatic instruments rising from DKK 27.7 million to DKK 61.8 million. Towards the end of the financi

ANNOUNCEMENT NO. 312 10 September 2026 ChemoMetec today approved the annual report for 2025/26, including the guidance for 2026/27, which is considered inside information. For the financial year 2026/27, ChemoMetec expects revenue in the range of DKK 545-575 million (2025/26: DKK 511.1 million) and EBITDA in the range of DKK 300-315 (2025/26: DKK 281.3 million). The annual report for 2025/26, which is released along with this announcement, sets out the underlying assumptions applied in the prepa

ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties’ solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement. The agreement covers the development of a connection kit between the Roche-owned Cedex® Bio Analyzer and the ChemoMetec-owned Xcytomatic® 30 (XM30) cell counting analyzer, as well as asp

ChemoMetec A/S announces its Annual Report for the financial year 2025/26 on Thursday, 10 September, 2026. Following the announcement ChemoMetec A/S will host a conference call on Friday, 11 September, 2026, at 3:00 p.m. CEST. CEO Martin Helbo Behrens and CFO Phillip Massie Price will present the Annual Report and answer questions. The conference will be held in English. Registration is available through this link. Further information Martin Helbo Behrens, CEOPhone: (+45) 81 10 06 80 Phillip Mas

ANNOUNCEMENT NO. 310 1 August 2026 Appointment of new CFO The board of ChemoMetec has appointed Phillip Massie Price as the new CFO with effect from 3 August 2026. Phillip Massie Price joins ChemoMetec from a position as Director, Corporate Finance at Unimed, a global healthcare group. Previously, he served as Interim Group CFO at LiqTech International, Inc., listed on Nasdaq in New York, where he led Group Finance. Phillip is 34 years old, has a background in auditing, and holds an MSc in Busin

ANNOUNCEMENT NO. 309 15 May 2026 Initiation of buy-back programme The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 9 October 2025. The authorisation is valid until the next Annual General Meeting, which will be held on 8 October 2026 and covers up to 10% of the share capital. At the start of the share buy-back programme, ChemoMetec A/S does not hold any own shares. The purpose of the share buy-back pro

As the pan-European STOXX Europe 600 Index concluded a turbulent week with modest gains, investor sentiment was buoyed by easing geopolitical tensions and robust corporate earnings across the region. However, concerns over potential U.S. tariffs on EU goods introduced some volatility into the markets. In this environment, identifying stocks that may be priced below their intrinsic value estimates can offer opportunities for investors seeking to capitalize on market inefficiencies and strong...

Trading statement for Q3 2025/26 (1 January – 31 March 2026) Growth in revenue and operating profit ChemoMetec’s revenue was up by 15% in the third quarter of 2025/26 to DKK 142.3 million from DKK 124.2 million in the year-earlier period. In local currencies, the revenue growth was 21%. To ensure continued compliance with applicable financial reporting regulation (IFRS), ChemoMetec adjusted the allocation of revenue between instruments and services. This has had a positive one-off effect on sale

ANNOUNCEMENT NO. 307 4 May 2026 Adjustment of accounting estimates contributes to an upgrade of revenue and operating profit guidance To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services. This has had a positive one-off effect on sales of instruments and EBITDA of DKK 15.1 million and means that a larger share of revenue will be recognised in the sale of instruments going forward. Based

Amid ongoing geopolitical tensions and fluctuating energy prices, European markets have experienced mixed performance, with the pan-European STOXX Europe 600 Index seeing a modest gain. In this uncertain environment, identifying stocks trading below their estimated fair value can present potential opportunities for investors seeking to capitalize on market inefficiencies.

ANNOUNCEMENT NO. 306 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CFO Kim Nicolajsen in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45)

As European markets navigate through volatility, with the pan-European STOXX Europe 600 Index recently hitting a new high but ending broadly unchanged, investors are keenly observing how AI disruption concerns and better-than-expected U.S. jobs data influence sentiment across the continent. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for those looking to capitalize on market inefficiencies.

ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with

ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26 Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was up 3% measured in local currencies, while in Danish kroner it was down to DKK 249.0 million, a year-on-year decrease of 1%. Despite this, EBITDA and the EBITDA margin showed a slight increase. Revenue was affected by a sharp slowdown in US demand, as many of our customers in the US